Targeting stroma to treat cancers.
All cancers depend on stroma for support of growth. Leukemias, solid tumors, cancer cells causing effusions, metastases as well as micro-disseminated cancer cells release factors that stimulate stromal cells, which in turn produce ligands that stimulate cancer cells. Therefore, elimination of stromal support by destroying the stromal cells or by inhibiting feedback stimulation of cancer growth is in the focus of many evolving therapies. A stringent evaluation of the efficacy of stromal targeting requires testing in animal models. Most current studies emphasize the successes of stromal targeting rather than deciphering its limitations. Here we show that many of the stromal targeting approaches, while often reducing tumor growth rates, are rarely curative. Therefore, we will also discuss conditions where stromal targeting can eradicate large established tumors. Finally, we will examine still unanswered questions of this promising and exciting area of cancer research.
Department of Pathology, Committee on Cancer Biology, Committee on Immunology, The University of Chicago, Chicago, IL 60637-5420, USA. bengels@bsd.uchicago.edu
Boris
B
Engels
Donald A
DA
Rowley
Hans
H
Schreiber
D018450:Disease Progression; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology / Q000628:therapy*; D019899:Paracrine Communication / Q000502:physiology*; D017154:Stromal Cells / Q000502:physiology*